Document is current
Any future updates will be listed below
-
Authors
Jarr, Kai-Uwe https://orcid.org/0000-0003-3376-6478
Ye, Jianqin https://orcid.org/0000-0003-4492-3897
Kojima, Yoko
Ye, Zhongde https://orcid.org/0000-0002-7817-3142
Gao, Hua https://orcid.org/0000-0002-1029-1476
Schmid, Sofie
Luo, Lingfeng
Baylis, Richard A. https://orcid.org/0000-0001-7040-7920
Lotfi, Mozhgan
Lopez, Nicolas https://orcid.org/0000-0003-0659-4500
Eberhard, Anne V. https://orcid.org/0000-0002-3158-2686
Smith, Bryan Ronain
Weissman, Irving L.
Maegdefessel, Lars
Leeper, Nicholas J. https://orcid.org/0000-0002-0905-2806
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (JA 2869/1-1:1, SFB1123)
Deutsche Herzstiftung (S/09/19)
Deutsches Zentrum für Herz-Kreislaufforschung (Junior Research Group)
U.S. Department of Health & Human Services | National Institutes of Health (R35 HL144475)
American Heart Association (EIA34770065)
- License Information
-
More Information
Article History
Received: 28 July 2021
Accepted: 26 January 2022
First Online: 7 March 2022
Competing interests
: I.L.W. and N.J.L. are cofounders and directors of Bitterroot Bio Incorporated, a cardiovascular company studying macrophage checkpoint inhibition. K.-U.J., Y.K., I.L.W. and N.J.L. have filed a provisional patent (US Application serial no. 63/106,794): ‘CD47 Blockade and Combination Therapies Thereof For Reduction Of Vascular Inflammation’. The remaining authors declare no competing interests.
